Ikarian Capital, LLC Clovis Oncology, Inc. Call Options Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 12, 2021	BUY	$4.13 - $6.41 $1.03 Million - $1.6 Million	250,000 Added 62.5%	650,000 $3.12 Million
Q3 2020 Nov 16, 2020	SELL	$4.82 - $7.72 $370,658 - $593,668	-76,900 Reduced 16.12%	400,000 $2.33 Million
Q2 2020 Aug 14, 2020	SELL	$5.69 - $9.69 $1.7 Million - $2.89 Million	-298,000 Reduced 38.46%	476,900 $3.22 Million
Q1 2020 May 15, 2020	BUY	$3.77 - $11.0 $984,724 - $2.87 Million	261,200 Added 50.85%	774,900 $4.93 Million
Q4 2019 Jan 31, 2020	BUY	$3.0 - $16.43 $1.54 Million - $8.44 Million	513,700 New	513,700 $5.36 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.